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Background of the study: The present investigation was designed with the intention to formulate versatile
5-fluorouracil (5-FU) matrix tablet that fulfills the therapeutic needs that are lacking in current cancer treatment and
aimed at minimizing toxic effect, enhancing efficacy and increasing patient compliance. The manuscript presents
the critical issues of 5-FU associate with cancer and surpasses issues by engineering novel 5-FU matrix tablets
utilizing chitosan- polycarbophil interpolyelectrolyte complex (IPEC).
Methods: Precipitation method is employed for preparation of chitosan and polycarbophil interpolyelectrolyte
complex (IPEC) followed by characterization with Fourier transform infrared spectroscopy (FT-IR), Differential
Scanning calorimeter (DSC) and X-ray Diffraction (XRD). 5-FU tablets were prepared by direct compression using
IPEC. Six formulations were prepared with IPEC alone and in combination with chitosan, polycarbophil and Sodium
deoxycholate. The formulations were tested for drug content, hardness, friability, weight variation, thickness,
swelling studies, in vitro drug release (buccal, vaginal and rectal pH), ex vivo permeation studies, mucoadhesive
strength and in vivo studies.
Results: FT-IR studies represent the change in spectra for the IPEC than single polymers.DSC study represents the
different thermo gram for chitosan, polycarbophil and IPEC whereas in X-ray diffraction, crystal size alteration was
observed. Formulations containing IPEC showed pH independent controlled 5-FU without an initial burst release
effect in buccal, vaginal and rectal pH. Furthermore, F4 formulations showed controlled release 5-FU with highest
bioadhesive property and satisfactory residence in both buccal and vaginal cavity of rabbit. 3% of SDC in
formulation F6 exhibited maximum permeation of 5-FU.
Conclusion: The suitable combination of IPEC, chitosan and polycarbophil demonstrated potential candidate for
controlled release of 5-FU in buccal, vaginal and rectal pH with optimum swelling approaching zero order release.
Keywords: Chitosan, Polycarbophil, Interpolyelectrolyte complex, pH independent drug releaseIntroduction
Extensive research has been made for the delivery of ac-
tive drugs through buccal, vaginal and rectal cavity. The
mucosa offers excellent opportunities to deliver active
drugs both locally and systemically [1]. Over the last
decade considerable progress in research towards the* Correspondence: mohamedsaif.xlnc@gmail.com
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for various diseases have been made.
Cancer is a disease involving all organs, races, ages
and sex of the humans. Among all types of cancer, Oro-
pharyngeal cancer, colorectal cancer contributes to
world most burden and cervical cancer accounts for lit-
tle extent. Oropharyngeal cancer develops in the part of
the throat just behind the mouth called the oropharynx.
Oropharynx includes the base of the tongue, soft palate,
tonsils, tonsillar pillars and back wall of the throat [2].oMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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lower part of uterus. About 90% of Oropharyngeal and
cervical cancers are squamous cells carcinoma that
begins in the epithelial lining in mouth and vagina.
Whereas in colorectal cancer columnar cells are affected.
Surgery, radiation therapy and chemotherapy are the
most common therapies for treating cancer.
In chemotherapy, most of the anticancer drugs are
parenterally administered attributable to poor oral bio-
availability; this can be due to either poor absorption or
significant first pass metabolism. However, limitation of
parental are need to be sterile, time consuming, pain on
administration and as also studies reported, approxi-
mately 90% of cancer patients prefer oral administration
than intravenous administration [3,4].
5-FU is the drug of choice in oropharyngeal caner,
colorectal cancer, stomach cancer and cervical cancer
[5]. Chemically, 5-FU is a dipodic acid and highly polar
in nature with pka values of 8.0 and 13.0 [6,7]. After oral
administration, 5-FU is poorly absorbed with erratic
variation in bioavailability ranging between 0 to 80%. 5-
FU after parenteral administration it is rapidly elimi-
nated with apparent terminal half life of approximately
8-20 min [8,9]. On intravenous administration 5-FU pro-
duces severe systemic toxic effects including gastrointes-
tinal, hematological, neural, cardiac and dermatological
origin [10]. These problems make 5-FU suitable candi-
date for Transbuccal/vaginal and rectal delivery.
Polymeric drug delivery systems are mainly designed
for the efficient delivery of active drug. Among various
polymeric drug delivery systems, interpolyelectrolyte
complexes are most new, efficient form of polymeric
carriers for novel drug delivery systems [11-14]. Chitosan
polycarbophil IPEC has established its potential in drug
delivery and have been most efficient form of IPEC com-
pared to other complexes [15-17].
Most publications on 5-FU focused only on single
drug delivery system like buccal gels, cervical patches,
colorectal drug delivery. Hardly any articles reported on
permeation studies and histological effects of 5-FU. Lit-
erature review revealed that there is no single drug deliv-
ery system available that can be given either through
buccal, vaginal or rectal route. The prime goal has to de-
sign 5-FU multipurpose tablets with greater efficacy, po-
tency, adoptability to need, minimal toxic effects and




5-FU obtained from Strides Arcolab Ltd., Bangalore,
India. Chitosan (Marine chemical, Cochin, India, Deace-
tylation degree: 85%, Viscosity: <200 mpa.s, Moisture
content: <10%, Ash content: <1%, Insoluble: <1%, pH: 3-6, Particle size: 80-100 mesh). Polycarbophil (Noveon
AA-1)(Arihantt Trading Co., Mumbai, India, nature:
pH:2.5-3, Ash content: 0.009 ppm, Density: (bulk) 0.19-
0.24 g/cm3. Equilibrium moisture content: 8-10%, pka:
6.0 ± 0.5, Glass transition temp: 100-105°C, Moisture
content: 2.0% max, Specific gravity: 1.41).
Sodium deoxycholate, microcrystalline cellulose and
Talc were from Zydus Cadila, India. All other chemicals
and reagents used were of analytical grade.
Methods
Preparation of chitosan- polycarbophil complex (IPEC)
3% w/v Chitosan aqueous acetic acid solution and 3% w/v
of polycarbophil acetic acid solution were mixed. The
chitosan solution was added slowly to the polycarbophil
solution under homogenization over a period of 20 min
(5000 rpm) and the mixture was then stirred for a period
of 1 hr at a speed of 1200 rpm with a mechanical stirrer.
The formed gel was separated under vacuum pump and
washed several times with a 2% v/v acetic acid solution to
remove any non complexed polymeric material. The gel
was dried in hot air oven and the dried complex was
ground with a grinder. The powder was passed through a
200 μm sieve and used for further study.
Fourier transform infrared (FT-IR) spectroscopy study
The infrared absorption spectra of Chitosan, polycarbo-
phil and IPEC were analyzed using a FT-IR spectropho-
tometer (8400S, Shimadzu, Japan). The pellets were
prepared by pressing the sample with potassium
bromide.
Differential scanning calorimetric (DSC)
Thermal analysis was carried out using a differential
scanning calorimeter (DSC 50, Shimadzu Scientific
Instruments, Japan) for Chitosan, polycarbophil and
IPEC. The samples were placed in an aluminum-sealed
pan and preheated to 200°C. The sample was cooled to
room temperature and then reheated from 40 to 400°C
at a scanning rate of 10°C/min.
Powder X-Ray diffraction
Powder x-ray diffraction patterns on Chitosan, Polycar-
bophil and IPEC were obtained by using an x-ray Dif-
fractometer (Miniflex II Desktop X-ray Diffractometer,
Rigaku Corporation, Tokyo, Japan). The samples were
scanned from 6° to 40° (2θ) with an increment of 0.02°
and measurement time of 10 s/increment.
Preparation of mucoadhesive matrix tablet
Mucoadhesive tablets were fabricated by direct compres-
sion method as shown Table 1. The accurate quantity of
5-FU and excipients were weighed. They were passed
through sieve and thoroughly mixed using mortar and
Table 1 Formulation chart
Ingredients F1 F2 F3 F4 F5 F6
5-flurouracil 20 20 20 20 20 20
IPEC 60 80 100 80 80 80
Chitosan —— —— —— 20 20 20
Polycarbophil —— —— —— 20 20 20
Sodium deoxycholate —— —— —— — 3 4.5
Microcrystalline cellulose 65 45 25 5 2 0.5
Talc 5 5 5 5 5 5
Weight in mg.
Total weight of tablet is 150 mg.
Pendekal and Tegginamat DARU Journal of Pharmaceutical Sciences 2012, 20:67 Page 3 of 11
http://www.darujps.com/content/20/1/67Pestle. The blend was lubricated and then compressed
into compacts by direct compression method using 8-
mm flat-faced punches in KBr press (Techno search,
Mumbai, India) at 1 ton pressure with a dwell time of
1 s.
Swelling studies
The swelling index of the prepared mucoadhesive 5-FU
tablets was determined by weighing five tablets and
recording their weights before placing them separately
in weighed beakers. The total weight was recorded (W1).
Four milliliters of phosphate buffer pH 6.8 (similarly
with simulated vaginal fluid pH 4.2 and pH 7.4) was
added to each beaker and then placed in an incubator at
37 ± 0.5°C. At time intervals of 2, 4, 6 and 8 h excess
water was carefully removed, and the swollen tablets
were weighed (W2). The experiment was repeated three
times, and the average W1 and W2 were reported.
The swelling index was determined from the formula.
SI ¼ W2W1ð Þ=W1X100
In vitro release of matrix tablets
The drug release rate from buccal compacts was studied
using the orbital shaking incubator using (Remi CIS 24,
India) 30 mL of phosphate buffer pH 6.8. The
temperature was maintained at 37 ± 0.5°C and 50 rpm
(rotation per min). For every one hour of time interval
3 mL sample was withdrawn, filtered through a Milli-
pore filter of 0.45 μm pore size and assayed spectro-
photometrically at 266 nm. Immediately after each
sample withdrawal, a similar volume of phosphate buffer
pH 6.8 was added to the dissolution medium.
The drug release rates from vaginal tablets were stud-
ied in 500 ml of simulated vaginal fluid pH 4.2 in type II
dissolution apparatus. The temperature was maintained
at 37 ± 0.5°C and 50 rpm. For every one hour of time
interval 10 mL sample was withdrawn, filtered through a
Millipore filter of 0.45 μm pore size and assayed spectro-
photometrically at 265 nm. Immediately after eachsample withdrawal, a similar volume of simulated vagi-
nal fluid was added to the dissolution medium.
In-vitro drug release for rectal tablets was performed
using the dissolution apparatus I; 500 mL phosphate
buffer (pH 7.4) maintained at 37 ± 0.5°C was used as a
dissolution medium. Basket was rotated at 50 rpm.
10 mL aliquots was taken at periodic time intervals and
replaced by equal volume of phosphate buffer. The solu-
tion was suitably diluted and the absorbance was taken
at 267 nm using UV visible Spectrophotometer.
Bioadhesive strength
Bioadhesive strength of the compacts was measure using
modified physical balance as recently discussed [18]. In
vitro bioadhesion studies were carried out using sheep
buccal mucosa and modified two-armed balance. The
phosphate buffer pH 6.8 was used as the moistening
fluid. A glass stopper was suspended by a fixed length of
thread on one side of the balance and was counter
balanced with the weights on the other side. Fresh sheep
buccal mucosa was collected from the slaughter house.
It was scrapped off from the connective tissues and a
thin layer of buccal mucosa was separated which was
stored in tries buffer until used for the bioadhesion
study. A circular piece of sheep buccal mucosa was cut
and fixed to the tissue holder and was immersed in
phosphate buffer pH 6.8 and the temperature was main-
tained at 37° ± 1°C. Then the tablet was fixed to a glass
stopper with the help of cyanoacrylate adhesive and it
was placed on the buccal mucosa by using a preload of
50gm and kept it aside for 3 min to facilitate adhesion
bonding. After preloading time, the preload was
removed and the weights were added on the other side
of the balance until tablet detaches from the sheep buc-
cal mucosa. The weight required to detach tablet from
buccal mucosa was noted.
Ex vivo permeation study
Permeation study was carried out for the optimized for-
mulation using Franz diffusion cell. The tablet was
placed in the donor compartment on the sheep mucosa.
The mucosal layer is on donor compartment. The recep-
tor compartment was filled with phosphate buffer pH
6.8. The temperature was maintained at 37 ± 0.5°C and
50 rpm. The amount of 5-FU permeated through sheep
mucosa was determined by withdrawing 3 ml of aliquots
from the receptor compartment using a syringe and im-
mediately replacing the same volume of solution.
In vivo x-ray studies
The in vivo X-ray studies were approved by the Institu-
tional Animal Ethical Committee of JSS College of
Pharmacy (Mysore, Karnataka, India). The study was
performed on healthy female rabbit, weighing between
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X-ray grade barium sulfate (20 mg of 5-FU was replaced).
The prepared tablet was placed in buccal mucosa of
healthy rabbit. During the study, the rabbit was not
allowed to eat or drink. The rabbit was exposed to x-ray
examinations and photographs were taken at 1st and 8th
hr after administration of the tablet. Similarly procedure
was followed for vaginal and rectal delivery.
Kinetic analysis
Drug release from simple swellable systems may be
described by the power law expression and is defined by
the following equation
Mt=M1 ¼ Ktn
Where Mt is the amount of drug released at time t,
M∞ is the overall amount of drug released, K1 is the re-
lease constant; n is the release or diffusion exponent and
Mt/M∞ is the cumulative drug concentration released at
time t (or fractional drug release).
The release exponent (n) value was used for inter-
pretation of the release mechanism from the compacts.
The dissolution data were modeled by using PCP disso
v2.01 (Bharathi Vidhyapeeth, Deemed University, Pune,
Maharashtra, India).
Statistical analysis
Statistical analyses of all data were undertaken using
Graph Pad prism version 5.0 (Graph pad software Inc,
San Diego, California, USA).
Results and discussion
In our previous paper, studies on CarbopolW 71 G and
Noveon AA-1(polycarbophil) polymers and the influence
of formulation expedients were evaluated in our labora-
tory on buccal bioadhesive tablet of Fluconazole [19].
Later, it was also shown in our laboratory that the inter-
polymer complex between Chitosan and CarbopolW
71 G as a suitable polymer for the development of novel
drug delivery of miconazole for candidiasis [20].
In the light of vast previous experience and literature
on CarbopolW 71 G and polycarbophil, we identified that
polycarbophil, Carbopol and chitosan polymers are well
suitable for particular pH. In contrast, chitosan-
polycarbophil interpolyelectrolyte complex showed high
potential as matrix former and used as new class of
polymer carriers for creating novel drug delivery system
[21]. Therefore based on the extensive review and previ-
ous experience on above cited polymers, chitosan-
polycarbophil interpolyelectrolyte complex are taken
into present investigation.Characterization of IPEC
The interaction between chitosan and polycarbophil has
been studied by several investigators [22,23]. The studies
indicated that IPEC could be formed by the electrostatic
interaction between the COO− group of polycarbophil
and NH3
+ group of chitosan. The protonation of chitosan
and dissociation of polycarbophil solution was success-
fully accomplished by solution of chitosan and polycar-
bophil in acetic acid solution. Subsequently, chitosan –
polycarbophil interpolymer complex were prepared from
these solutions. Figure 1 shows the superimposed IR
spectra of Chitosan, polycarbophil and IPEC in 1000-
2000 cm-1 and 1400-1800 cm-1.
The degree of deacetylation of Chitosan is 85%, the
amine group of 2-aminoglucose unit and the carbonyl
group of 2-aminoglucose unit of chitosan showed ab-
sorption bands at 1589 and 1656 cm-1, respectively [24].
Polycarbophil exhibits a broad band at 1713 cm-1
assigned to C = O stretching (hydrogen-bonded). The
weak band at 1415 cm-1 is due to the symmetric stretch-
ing of carboxylate anion (COO−), bands 1230 and
1160 cm-1 are attributed to the C-O stretching [25,26].
In IR spectra, spectra of the physical mixture of two
polymers or immiscible polymers will be the sum of the
spectra of the individual compounds, whereas polymers
after electrostatic interaction, there will be changes in
the IR spectra such as Wave number shifts, band broad-
ening and new absorption bands that are evidence of the
polymers miscibility [27]. In IR spectra of Chitosan-
polycarbophil IPEC, a new and strong band is observed
at 1561 cm-1. This band can be assigned due to the over-
lapping of asymmetric COO- stretching vibration of
polycarbophil and the NH3
+ asymmetric bending vibra-
tion of chitosan which is agreement with literature to be
located between 1550–1610 cm-1 [28]. In addition, an-
other band at approximately 1402 cm−1 is a further evi-
dence of the interaction because it is attributed to the
symmetric COO− stretching vibration [29].
Figure 2 shows the DSC thermo grams of chitosan,
polycarbophil and IPEC. The DSC thermo grams of pure
chitosan, exhibits one broad endothermic peak at 110°C
associated to the evaporation of bound water, a glass
transition at 240°C and an exothermic peak at about
320°C attributable to the polymer degradation. This
includes saccharide rings dehydration, depolymerization
and decomposition of deacetylated and acetylated chito-
san units [30,31]. These peaks are agreement with other
reported studies [32,33]. Polycarbophil thermo gram
exhibits two endothermic peaks at 91°C and ~245°C.
The first endothermic peak is short and narrow peak
assigned to the evaporation of water from hydrophilic
groups in the polymers and the second one corresponds
to a thermal degradation through intermolecular anhyd-
ride formation and water elimination [34,35]. The
Figure 1 FT-IR Spectra of Chitosan, Polycarbophil and IPC in 2000-1000 and 1800-1400 cm-1.
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endothermic peaks. The first one and second is asso-
ciated with the vaporization of water situated at ~53°C
and ~100°C in the chitosan polycarbophil IPEC. The
second endothermic peak is probably related with the
cleavage of the electrostatic interactions between the op-
positely charged polymers, since it is not observed for
the pure compounds. The appearance of new broad
endotherm at 250°C is indicative of a compound with
distinctive thermal behavior properties.
The X-ray diffraction of Chitosan, polycarbophil and
IPEC were shown in Figure 3. The powder x-ray diffrac-
tion pattern of chitosan powder showed two prominent
diffraction peaks at 10.6° (2θ) and 19.64° (2θ). A shoulder
peak appears at 21.74° and also minor peak appears at
26.62°. The two prominent crystalline peaks at 10.6° and
19.64° are typical fingerprint for chitosan which were
related to the hydrated and anhydrous crystals respectively
[36]. Polycarbophil showed peaks at 18.88°, whereas IPEC
showed peak at 19.92°. The typical peaks of chitosan
disappeared and the IPEC showed an amorphousmorphology after completing. The integration of polycar-
bophil into chitosan disrupted the crystalline structure of
chitosan, hindering the formation of hydrogen bonding
between amino groups and hydroxyl groups.
Characterization of matrix tablets
Pharmaceutical properties
The results of pharmaceutical properties are summarized
in Table 2. The matrix tablets showed a diameter of
8 mm with negligible variation and therefore not
included in the table. All the formulations showed satis-
factory values within the limits of conventional oral
tablets stated in the Indian Pharmacopoeia [37].
Swelling studies
F3 formulation containing higher concentration of IPEC
showed pronouncedly higher swelling capabilities in va-
ginal, buccal and rectal pH compare to F1 and F2 for-
mulation (lesser concentration of IPEC). The swelling
for F3 formulation in vaginal, buccal and rectal pH was
found to 802%, 798%, and 797% respectively. Further,
Figure 2 Superimposed DSC thermograms of chitosan, polycarbophil and IPEC.
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lation in vaginal pH 4.2 reduces the swelling to 445%.
Nearly same degree of swelling was observed for F5 and
F6 as that of the formulation F4. The addition of sodium
deoxycholate doesn’t significantly alter the swelling in F5
and F6. The comparison of degree of swelling of all for-
mulations in vaginal pH 4.2 was shown in Figure 4a. In
pH 6.8, F2 formulation showed 785% of swelling i.e.
lesser than F3 formulation. The F4 formulation found to
be having 495% of least swelling; this may be explained
due to dissociation of carboxylic group of polycarbophil
in buccal pH 6.8. Swelling profiles of formulations in pH
6.8 was shown in Figure 4b. In pH 7.4, F4 formulation
exhibited swelling of 481% that is as nearly similar in pH
4.2 and pH 6.8. Nearly same degree of swelling was
observed for F5 and F6 as that of the formulation F4.Swelling profiles of formulations in pH 7.4 was shown in
Figure 4c.
These findings indicate the presence of IPEC alone in
matrix tablet exhibit slow uniform pH independent swel-
ling degree and also the presence of chitosan and poly-
carbophil in IPEC matrix tablets alters the swelling
degree. Therefore the mechanism of drug release from
IPEC matrix tablets was affected by the presence of chit-
osan and polycarbophil.
Bioadhesion studies
The mucoadhesive strength for all the formulations was
shown in Figure 5. F1 formulation containing only IPEC
shows least detachment force this may be explained due
to the lacking of free functional groups which probably
involved in the adhesion of the mucosa. F2 formulation
Figure 3 Superimposed XRD spectra of Chitosan, polycarbophil and IPEC.
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detachment force, even further increase in IPEC concen-
tration in F3 formulation doesn’t alters the detachment
force. F4 formulation shows highest detachment force,
this may be due to availability of free functional groups.
F5 & F6 formulation containing sodium deoxycholate
doesn’t have any impact on the detachment force.
These findings indicate the presence of IPEC alone
doesn’t exhibit sufficient bioadhesion hence the presence
of other polymers is necessary for development of bioad-
hesive matrix tablets. Therefore suitable combination of
polymers along with IPEC is selected for producing suf-
ficient bioadhesion without altering properties of IPEC.Table 2 Pharmaceutical properties
Formulation code Thickness (mm) Hardness (N)
F1 2.03 ± 0.01 71 ± 3
F2 2.01 ± 0.05 72 ± 2
F3 2.03 ± 0.01 72 ± 3
F4 2.03 ± 0.02 73 ± 1
F5 2.01 ± 0.02 73 ± 3
F6 2.02 ± 0.02 73 ± 2In vitro drug release studies
In vitro drug release study of formulations in pH 4.2, 6.8
and 7.4 was shown in Figure 6a, b and c respectively.
Initially 5-FU matrix tablets were made from IPEC and
their in vitro drug release investigated and exhibited
controlled release properties without any initial burst
effect in buccal, vaginal and rectal pH .F1 & F2 for-
mulations exhibited controlled drug release in buccal,
vaginal and rectal pH with zero-order drug release.
But F3 formulation, retarded drug release up to 70%
in buccal, vaginal and rectal pH. Higher increase in
concentration of IPEC forms gel layer around tablets that
retards the drug release up to 70%. In spite of excellentFriability (%) Weight (mg) Drug content (%)
0.08 149.4 ± 0.43 99.90 ± 0.09
0.09 149.2 ± 1.00 99.91 ± 0.08
0.06 150.0 ± 0.57 99.92 ± 0.05
0.05 150.1 ± 1.00 99.94 ± 0.08
0.03 149.2 ± 0.52 99.95 ± 0.05
0.04 149.2 ± 0.44 99.92 ± 0.05
ab
c
Figure 4 a: Swelling studies of formulations in pH 4.2. b:
Swelling studies of formulations in pH 6.8. c: Swelling studies of
formulations in pH 7.4.
Figure 5 Mucoadhesive strength of formulations.
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rectal pH, formulations containing IPEC (F1, F2 & F3)
fails to attain sufficient mucoadhesive strength (men-
tioned in mucoadhesive studies). The study represents
that alone IPEC can sustain the drug release but doesn’t
produces mucoadhesion. Hence, addition of chitosan and
polycarbophil for IPEC formulation exhibited drug re-
lease up to 90% in 8 h in buccal, vaginal and rectal pH.
This may be due to undissociation of carboxylic group of
polycarbophil in pH 4.2, thereby neutralizing the gelforming ability of chitosan. In buccal pH 6.8, the polycar-
bophil has the ability to swell and retard the drug release
that is due to dissociation of carboxylic group. This prop-
erty of polycarbophil is neutralized by chitosan that pos-
sesses gel forming property only in acidic pH. Similarly
in rectal pH 7.4 the properties of polycarbophil and chit-
osan don’t altered, hence similar drug profile was seen as
in buccal and vaginal pH. F5 & F6 formulation contain-
ing SDC exhibited similar drug release profile as F4 for-
mulation (Data not mentioned).
F4 formulation was subjected for kinetic study and the
Correlation coefficients for F4 formulation in vaginal,
buccal and rectal pH were found to 0.9964, 0.9957 and
0.9966 respectively. According to drug release exponent
value (n), it is clear that F4 formulation approached
zero-order drug release in vaginal, buccal and rectal pH
(n value is 0.9). Thus the drug release is predicted as
function of swelling for F4 formulation.
To confirm the similarity of F4 formulation dissolution
profiles in buccal, vaginal and rectal pH, the similarity
factor (f2) was used and was found above 80. Since the
f2 values were higher than 50, these results confirmed
that the drug release profiles were almost similar for F4
formulation for both buccal, vaginal pH and rectal pH.
Ex vivo permeation studies
5-FU permeation from formulations F5 and F6 across
sheep mucosa over a period of 8 h is shown in Figure 7.
The maximum permeation of 5-FU from F5 was 97% at
8 h compared with 63% from F6. Regression of the linear
portions of the two plots gave Slopes and intercepts
from which the permeation flux (slope divided by muco-
sal surface area) of F5 and F6 were calculated to be
8.5866 and 5.1333 mg/cm2/h, respectively. While perme-
ation coefficients were found be 2.1466 and 1.2833 cm/h
for F5 and F6 formulations, respectively.
In formulation F5 addition of SDC 2% increased the cu-
mulative percentage of drug permeated to 63%. This may
be due to SDC extracted only mucosal lipid from the
intercellular spaces. Thus, this enhances the diffusivity of
ab
c
Figure 6 a: Dissolution profile of formulations F1-F4 in pH 4.2.
b: Dissolution profile of formulations F1-F4 in pH 6.8. c: Dissolution
profile of formulations F1-F4 in pH 7.4.
Figure 7 Ex vivo permeation studies of F5 & F6 formulation.
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crease in concentration of SDC (F6),i.e., 3%, increased the
drug permeation up to 97% thus SDC in 3% extract lipids
from the cell membranes, along with the extraction of
mucosal lipid from the intercellular spaces by the forma-
tion of micelles. This resulted in enhancing passive diffu-
sivity of the 5-FU via transcellular (crossing the cell
membranes and entering the cell) and par cellular routes
[38]. It was mentioned that SDC can also cause theuncoiling and extension of the protein helices, which leads
to opening of the polar pathways for diffusion [39]. All
these effects might contribute to enhancing the perme-
ation of the drug.
In vivo X-ray studies
After administration of the optimized formulation (F4),
developed by using barium sulfate, the duration of the
tablet in the buccal, vaginal and rectal cavity was moni-
tored by radiograms (Figure 8). The tablet adheres to the
buccal, vaginal and rectal mucosa. The buccal tablet
swells and retained till 8 h with little reduction in tablet
size, as the tablet swells certain part of the tablet was
swallowed by rabbit thereby the tablet size reduces.
Whereas the tablet in vaginal cavity swells in 1 h and lit-
tle reduction of size at 8 h. In rectal cavity tablet
remained in cavity till 8 h.
Conclusion
All formulations studied showed good pharmaceutical
properties. However, in consideration of swelling, drug
release and mucoadhesion, some important differences
have been highlighted. Formulation F3 containing only
IPEC exhibited almost similar swelling in vaginal, buccal
and rectal pH. Other two formulations F1 & F2 also con-
taining lesser amount of IPEC produced less swelling
than F3 formulation. The addition of polymer blends
(chitosan and polycarbophil) to F3 formulation showed
optimum swelling. These formulations, in fact, in
addition to good swelling, lack sufficient mucoadhesion.
F4 formulation demonstrated high mucoadhesive prop-
erty. Further, the addition of SDC doesn’t produce im-
pact on mucoadhesion.
On the basis of these properties, it is clear that IPEC
alone doesn’t produce desired response hence, addition
of polymeric blends is essential for developing the drug
delivery system. The in vitro drug release study of F3
formulation demonstrated potential excipient for control
Figure 8 X-ray radiographic images of buccal and vaginal cavity at 1 and 8 h after ingestion of BaSO4-loaded optimized F4 matrix
tablet.
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The matrix system with suitable combination of IPEC
with polymeric blends (chitosan and polycarbophil) in
F4 formulation able to produce desired drug release,
bioadhesion, swelling and satisfactory in vivo residence.
The desired bioadhesion can be achieved only with the
addition of chitosan and polycarbophil; hence suitable
combination played key role in the bioadhesion and sub-
sequently maintains the pH independent drug release
without initial burst release pattern. The addition of 3%
Sodium deoxycholate to the F4 formulation demon-
strated necessary 5-FU permeation.
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